Roche This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others ...

Driving innovation & growth Bill Anderson | CEO Roche Pharmaceuticals J.P. Morgan Healthcare Conference, 11 January 2022 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ mater ...

Rejuvenation, Diversification, Transformation Severin Schwan | CEO Roche BofA Global Healthcare Conference, London, September 2021 Covid: How we see the future, and our contribution bring society back to normal Strong rejuvenation and diversification - passion about innovation 2 SARS-CoV-2: Our outstanding contribution battling the pandemic > 1 million hospitalized patients received Roche's treatments Atea Positive Ph II interim analysis collaboration AT-527 in hospitalized patients signed Regeneron RECOVER ...

Roche: Rejuvenation and Diversification Teresa Graham | Head Pharma Global Product Strategy (GPS) Bernstein SDC Conference Strong portfolio rejuvenation and diversification HY 2016 HY 2011 HY 2021 AHR CHFm CHFm CHFm 21,671 AHR AHR 16,815 19,460 Metabolism/Bone Renal anemia Other Immunology Neuroscience Oncology Ophthalmology Infectious diseases Hemophila A 2 Source: Pharma HY sales as reported in HY reports; AHR=Avastin, Herceptin, MabThera/Rituxan Note: HY 2011 – Inflammation/Autoimmune/Transplantation sho ...

Roche Pharma Day 2021 14 September 2021 Roche Pharma Day 2021 Welcome Karl Mahler | Head of Investor Relations Agenda Welcome Karl Mahler, Head of Investor Relations Pharma Strategy: Sustainable growth by delivering more patient benefits at reduced cost to society Bill Anderson, CEO Roche Pharmaceuticals Commercial Opportunities: Near-term growth drivers Teresa Graham, Head Pharma Global Product Strategy (GPS) Short break Late Stage Pipeline Oncology & Non-malignant Hematology Levi Garraway, Chief Medical O ...

Roche Holding AG (OTCQX:RHHBY) Q2 2021 Earnings Conference Call July 22, 2021 8:00 AM ET Company Participants Karl Mahler - Head, IR Severin Schwan - CEO & Executive Director William Anderson - CEO, Roche Pharmaceuticals Thomas Schinecker - CEO, Roche Diagnostics Alan Hippe - Chief Financial & Information Officer Conference Call Participants Richard Parkes - Exane BNP Paribas Simon Baker - Redburn Jo Walton - Crédit Suisse Michael Leuchten - UBS Sachin Jain - Bank of America Merrill Lynch Richard Vosser - J ...

Roche Roche HY 2021 results Basel, 22 July 2021 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements co ...

| --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|--------------------------------------------------| | | | | | | | | | | | | | target discovery, drug discovery and development | May 2021 Executive summary • Genentech and Roche are innovation companies • Drill-deep science delivers breakthrough and transformative medicines • Substantial innovation-focused investment fuels growth • Robust portfolio and leadership in key areas • Continued oncology leadership: molecular and immuno- ...